World Health Organization site
Skip Navigation Links

Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ISRCTN
Last refreshed on: 14 July 2014
Main ID:  ISRCTN40020296
Date of registration: 09/10/2008
Primary sponsor: Drugs for Neglected Diseases initiative (DNDi) (Switzerland)
Public title: A phase IV randomised study to assess the tolerability of artesunate-amodiaquine (AS-AQ) (Winthrop® fixed dose combination [FDC]) and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia N/A
Scientific title:
Date of first enrolment: Sep 29 2008
Target sample size: 1000 patients
Recruitment status: Completed/Not recruiting
Study type:  Interventional
Study design:  A randomised, single-blind, two-armed, single-centre comparative study  
Countries of recruitment
Key inclusion & exclusion criteria
Inclusion criteria: 1. Aged greater than or equal to 6 years, either sex
2. Weight greater than or equal to 18 kg
3. Symptoms of malaria defined as fever (axillary temperature greater than or equal to 37.5°C), or history of fever in previous 48 hours
4. Microscopic confirmation of asexual stages of P. falciparum or mixed infection
5. Willingness to attend for follow-up
6. Signed informed consent by patient or responsible caregiver

Exclusion criteria: 1. Pregnancy (pregnancy test to be performed in women of childbearing age)
2. Severe malaria
3. AS-AQ or AL treatment at appropriate dose or more than two doses of another antimalarial in the previous 4 weeks
4. Known hypersensitivity to artemisinin derivates or amodiaquine, or artemether-lumefantrine
5. Severe anaemia (less than 5 g/dl haemoglobin)
6. Concomitant febrile illness if additional medication is required other than antipyretics

Age minimum:
Age maximum:
Health Condition(s) or Problem(s) studied
Patients will be equally randomised into the following treatment groups:
1. Artesunate-amodiaquine (AS-AQ Winthrop®, Sanofi-Aventis): tablet strength AS/AQ 100/270 mg. Participants will be dosed according to body weight:
18 - 35.9 kg = 1 x 100/270 mg tablet once daily
Greater than 36 kg = 2 x 100/270 mg tablets once daily
2. Artemether-lumefantrine (Coartem, Novartis): tablet strength A/L 20/120 mg. Participants will be dosed according to body weight:
15 - 24.9 kg = 2 x 20/120 mg tablets twice daily, 8 - 12 hour between dosages
25 - 34.9 kg = 3 x 20/120 mg tablets twice daily, 8 - 12 hour between dosages
Greater than 35 kg = 4 x 20/120 mg tablets twice daily, 8 - 12 hour between dosages

For both arms: 3 days of treatment + 25 follow-up days (study duration/patient = 28 days).
Primary Outcome(s)
To describe clinical tolerability of a fixed dose of AS-AQ (Winthrop® FDC) in adults and children over 6 years with uncomplicated P. falciparum malaria compared to a non-AQ containing reference therapy, i.e. artemether-lumefantrine. The clinical tolerability will be defined as the occurrence of most common adverse events.
Secondary Outcome(s)
1. To describe serious adverse and drug related adverse events occurring within 1 month of drug administration for both treatment
2. To assess efficacy of treatment at 28 days (polymerase chain reaction [PCR] genotyping corrected)
3. To describe day 0 and day 7 blood levels of desethyl-amodiaquine and lumefantrine
Secondary ID(s)
Source(s) of Monetary Support
Drugs for Neglected Diseases initiative (DNDi) (Switzerland)
Secondary Sponsor(s)
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history